Moreover, we treated the LEGOs with the CDK inhibitor Zotiraciclib targeting CDK1/2, which was highly activated in all the mutant organoids, and observed that all LEGOs were highly sensitive to Zotiraciclib treatment (Fig. 6j), suggesting that CDK1/2 are valuable therapeutic targets in GBM. Here, CDK1 is linked to glioblastoma.